I am delighted to invite you to take part in this international Masterclass webinar on Major Depressive Disorder (MDD) which is organised and sponsored by H. Lundbeck A/S. This promotional webinar will cover a broad range of topics highly relevant to your clinical practice.
The focus of this Masterclass webinar is on how patient perspectives can help improve outcomes in the acute and maintenance phases of MDD treatment. This session will consider common challenges faced by both patients and healthcare professionals in the management of MDD, including the impact of individual symptoms such as emotional blunting and anhedonia on treatment outcomes. We will highlight key data from studies involving patient perspectives and discuss on how these can shape the clinical management of MDD. Some of the latest clinical data on vortioxetine* will be featured in these contexts.
This interactive Masterclass webinar will include an engaging mix of plenary presentations, lively panel discussions, and multiple Q&A opportunities with our international faculty. You will have ample opportunity to hear expert perspectives on common clinical challenges encountered during the acute and maintenance phases of MDD treatment. We hope that attending this webinar will broaden your knowledge in this area, and that you will be able to use these new insights to support your clinical practice, as well as sharing learnings with your colleagues.
*Brintellix® (vortioxetine) is indicated for the treatment of major
depressive episodes in adults
Professor Andrea Fagiolini is currently Chairman of the Department of Mental Health and Sensory Organs, Chief of Medical Services of the Division of Psychiatry, and Residency Training Director at the University of Siena School of Medicine, Italy.
Previously, Professor Fagiolini spent over 10 years on the faculty at the University of Pittsburgh Medical School, PA, USA, where he served as Associate Professor of Psychiatry and Medical Director of the Bipolar Disorder Centre and the Depression and Manic Depression Prevention Program.
Professor Fagiolini’s research interests include pharmacological treatment of mood, anxiety and psychotic disorders as well as treating and preventing physical comorbidity in patients with mental illness. He has published more than 400 books and peer-reviewed papers primarily focusing on the pharmacological treatment of psychiatric disorders.
Professor Fagiolini received his medical training from the University of Pisa School of Medicine and completed his psychiatric residency at the University of Modena, Italy.
Dr Stavroula Bargiota is a psychiatrist-psychotherapist. She holds a MSc degree in primary health care and a PhD in psychopharmacology.
She works as a Clinical Psychiatrist at her own two private medical centres in Thessaloniki and Larissa, Greece. She has worked for years as Lead Clinical Psychiatrist at the Community Health Clinic of Neapoli-Sykies Thessaloniki.
She has also worked as Honorary Specialist Registrar and Visitor Researcher at South London and Maudsley NHS Trust and at the Institute of Psychiatry, Psychology & Neuroscience, King’s College, London, UK. She is a Scientific Associate at the Medical School of Aristotle University of Thessaloniki Medical School and Post-doctoral Research Fellow at the University of Thessaly, Larissa, Greece. She is responsible for research projects as well as the training of medical students, MSc students and resident psychiatrists.
Her research interests include treatment-resistant depression, biomarkers, linguistic indicators for early detection of depression, resilience in depressive and bipolar disorders and early intervention in psychosis. She is a TEDx speaker and she has been invited to numerous scientific presentations in mass media as an expert in psychiatry.
Professor Gregor Hasler was born in Basel, Switzerland. He is a Swiss psychiatrist and psychotherapist.
From 2003 to 2006 he was a visiting research fellow at the Mood and Anxiety Disorders Program at the National Institute of Mental Health (supervisors: Wayne C. Drevets, Dennis S. Charney, Husseini Manji). He uses positron emission tomography imaging, magnetic resonance spectroscopy, and pharmacological challenges to test the reward system in mood, anxiety and eating disorders (dopamine, glutamate, serotonin).
Professor Hasler is Professor and Chair of Psychiatry at the University of Fribourg, Switzerland. His research is supported by the Swiss National Science Foundation, and he has received numerous awards for his scientific work, including the National Alliance for Research on Schizophrenia & Depression (NARSAD) Independent Investigator Award and the Robert Bing Award from the Swiss Academy of Medical Sciences.
He is the President of the Swiss Society for Pharmacovigilance in Psychiatry and President of the Swiss Society for Bipolar Disorder. His h-index is 50 (2022).